Most recently, a family of quinoline-based positron emission tomography (PET)/computed tomography (CT) tracers were derived from a FAP inhibitor (FAPI) and demonstrated promising uptake in multiple cancer entities, including prostate cancer (PC) [8–10]. Here, FAP is linked to prostate cancer.